Trial reportArchives of dermatological research2025
Cryoblebbing with 5-fluorouracil versus cryoblebbing with melanocyte keratinocyte transplant procedure or cryoblebbing alone in treatment of stable vitiligo.
Trial report in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both the surgical non-cultured melanocyte-keratinocyte transplant procedure (MKTP) and intradermal injection of 5-Fluorouracil (5-FU) are effective in the treatment of vitiligo. Intrablisters injection of MKTP was done in one study with better results than MKTP application after ablative CO2 laser of the reciepient area. However, intrablister injection of 5-FU was not done before. To compare the efficacy of 5-FU, MKTP after preparation of the recipient site by cryoblebing in the treatment of stable vitiligo. Treatment efficacy was evaluated clinically, histopathologically, and immunohistochemically. This prospective, single-blinded, randomized comparative study included 20 patients with stable vitiligo in 128 areas. The recipient sites were prepared by cryoblebbing. The blisters were injected with either a suspension of MKTP in area A (MKTP group, 49 areas), 5-FU in area B (5-FU group, 48 areas) or left without injection in area C (control group, 31 areas). The assessment was performed 6 months after the procedure based on the percentage of repigmentation, histopathologically and immunohistochemically for the pigmented lesions. Six months after treatment, the mean percentage change in repigmentation was 82.96% ± 31.46% in the MKTP group, 44.79% ± 39.38% in the 5-FU group, and 28.23% ± 24.00% in the control group.The median of the percent change was 100%, 37.5% and 25% in MKTP group, 5-FU group and control group, respectively, with a significant difference (P < 0.001) between the groups. After treatment, H&E-stained sections from the repigmented lesions showed the reappearance of melanocytes (MCs) and melanin pigmentation, especially in the MKTP group followed by 5-FU. Immunohistochemical staining revealed large MCs with an increased density of reactions and dendricity with positive expression of Melan A, and HMB45 especially in the MKTP and 5-FU groups. Intrablister injection with 5-FU appears to be effective for the management of stable vitiligo with less efficacy than MKTP.
Indexed as
Identifiers
39825923What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.